Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 1.00 |
| ▸ | LAP3 | P28838 | 1/20 | 1.00 |
| ▸ | PPARG | P37231 | 3/20 | 0.54 |
| ▸ | PPARA | Q07869 | 3/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL220808 | 1.00 | LTA4H (1.00) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL220809 | 1.00 | LTA4H (1.00) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL8537520 | 0.90 | LAP3 (0.81) | LTA4HLAP3 | |
| SCHEMBL6551873 | 0.90 | LAP3 (0.81) | LTA4HLAP3 | |
| SCHEMBL3445511 | 0.90 | LAP3 (0.81) | LTA4HLAP3 | |
| SCHEMBL5811902 | 0.89 | LTA4H (0.80) | LTA4HLAP3PPARGPPARAFFAR1 | |
| Hydrochloric Acid SCHEMBL11089598 | 0.89 | LAP3 (0.79) | LTA4HLAP3 | |
| SCHEMBL6561218 | 0.85 | LTA4H (0.73) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL1855604 | 0.85 | LTA4H (0.73) | LTA4HLAP3PPARGPPARAFFAR1 | |
| SCHEMBL8413771 | 0.85 | LTA4H (0.73) | LTA4HLAP3PPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | MEDA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | BIOLIPOX AB (SE) | 2008-04-03 | — | — | US | disclosed |
| EP-0920422-A1 | CRYTALLINE FORM OF 4-[5-METHYL-3-PHENYLISOXAZOL-4-YL]BENZENESULFONAMIDE | G.D. SEARLE & CO. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998006708-A1 | CRYSTALLINE FORM OF 4-[5-METHYL-3-PHENYLISOXAZOL-4-YL]BENZENESULFONAMIDE | G.D. SEARLE & CO. (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220583-A1 | Method and composition for treating inflammatory disorders | LIPA, HRH2, HRH1 | LTA4H 6/4885LAP3 1310/4885PPARG 702/4885 |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTA4H 6/4885LAP3 1310/4885PPARG 702/4885 |
| US-20080081835-A1 | Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas | LTB4R, LTA4H, LTA | LTA4H 2/4885LAP3 1896/4885PPARG 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.